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Abstract
An overview of the development of anti-tumor organotin derivatives in selected classes of
compounds is presented and discussed. High to very high in vitro activity has been found,
sometimes equaling that of doxorubicin. Solubility in water is an important issue, dominating
the in vivo testing of compounds with promising in vitro properties. The cytotoxicity of the
compounds was increased by the presence of a bulky group, an active substituent or one or
more polar substituents. Polar substituents may also improve the water solubility. Although
organotin derivatives constitute a separate class of compounds, the comparison with cisplatin
is inevitable. Among the observed toxicities, neurotoxicity, known from platinum cytostatics,
and gastrointestinal toxicity, typical for many oncology drugs, have been detected. Further
research to develop novel, useful organotin anti-tumor compounds should be carried out.
Introduction
Platinum compounds such as cisplatin [1,2] and carboplatin [3] have found wide
application in cancer chemotherapy. Testicular, ovarian and bladder cancer have been
treated successfully by combinations containing these drugs. Also small cell lung cancer as
well as non small cell lung cancer have been shown responsive to platinum chemotherapy.
Also other platinum compounds are under investigation for anti-cancer treatment: e.g.
ormaplatin and oxaliplatin [4]. In addition to platinum compounds, derivatives of other
metals are being investigated for their anti-tumor properties e.g. titanocene [5].
The disease oriented strategy of the NCI makes use of a disease oriented primary screen.
This screen consists of a panel of 60 different human tumor cell lines [6,7]. The NCI screen
provides a tool for structure-activity relationships, new members of known mechanistic classes
can be found and new mechanistic classes can be discovered. In the present work, the NCI
approach was followed and use was made of an in vitro primary screen with seven human
tumor cell lines, of which five belong to the NCI panel.
The next step is the testing of promising new derivatives in human tumor xenografts in
nude mice [8,9]. In vivo testing is in general more time consuming than in vitro testing. In
particular nude mice experiments are rather elaborate due to the nature of the animal and
the test and evaluation period. Therefore a murine tumor model was selected. Initially, use
was made of the mouse L1210 leukemia [10], later on, the mouse Colon 26 was chosen
[11,12]. This model was expected to possess a higher predictive value than the L1210.
Subsequently the application of human tumor xenografts in nude mice can be considered
for further characterization of the new derivatives.
In the present study the results of the in vitro and in vivo testing of organotin compounds
will be summarized and discussed. As a reference drug, cisplatin will be used. Organotin
compounds may yield new leads for the development of anti-tumor drugs, which display
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another spectrum of antitumor activity, may show non-cross-resistance with platinum drugs
and may possess less or different toxicity as compared to platinum compounds.
Materials and methods
Instruments and Procedures
Instruments and procedures have been described in the papers of the derivatives referred
to below.
Synthesis
The synthesis and characterization of the compounds have been presented in the.
references pertaining to the compounds discussed below.
Antitumor tests
The following human tumor cell lines have been used in the in vitro tests: MCF7 breast
cancer, EVSA-T breast cancer, WIDR colon cancer, IGROV ovarian cancer, M19 MEL
melanoma, A498 renal cancer and H226 non small cell lung cancer. MCF7 is estrogen
receptor (ER)+/progesteron receptor (PgR)+ and EVSA-T is ER-/PgR-. The cell lines WIDR,
M19 MEL, A498, IGROV and H226 belong to the anti-cancer screening panel of the
National Cancer Institute, USA [6].
Prior to the experiments, a mycoplasma test was carried out on all cell lines and found to
be negative. All cell lines were maintained in a continuous logarithmic culture in the
standard growth medium RPMI 1640 with Hepes and phenol red. The medium was
supplemented with 10% fetal calf serum (FCS), penicillin 1001U/ml and streptomycin
100pg/ml. The cells were mildly trypsinized for passage and for use in the experiments.
RPMI and FCS were obtained from Life Technologies (Paisley, Scotland).
Sulforhodamine B (SRB), dimethylsulphoxide (DMSO), ethanol, penicillin and streptomycin
were obtained from Sigma (St.Louis, MO, USA), trichloroacetic acid (TCA) and acetic acid
from Baker BV (Deventer, NL) and phosphate buffered saline (PBS) from NPBI BV (Emmer-
Compascuum, NL).
The test and reference compounds were dissolved to a concentration of 238095 ng/ml in
full medium, by 21 fold dilution of an ethanol solution which contained 1 mg of
compound/200 !1. Compounds which were found to be insoluble in ethanol were dissolved in
DMSO.
The experiments were started on day 0. On day 0, 150 pl of trypsinized tumor cells (1500
2000 cells/well) were plated in 96-wells flatbottom microtiter plates (Falcon 3072, BD). The
plates were preincubated for 48 hr at 37C, 8.5% CO2 to allow the cells to adhere. On day 2,
a threefold dilution sequence of ten steps was made in full medium, starting with the 238095
ng/ml stock solution. Every dilution was used in quadruplicate by adding 50 1 to a column of
four wells. This results in a highest concentration of 59523 ng/ml present in column 12.
Column 2 was used for the blank. To column 1, PBS was added to diminish interfering
evaporation. On day 7, the incubation was terminated by washing the plate twice with PBS.
Subsequently the cells were fixed with 10% trichloroacetic acid in PBS and placed at 4C for
one hour. After five washings with tap water, the cells were stained for at least 15 minutes
with 0.4% SRB dissolved in 1% acetic acid. After staining, the cells were washed with 1%
acetic acid to remove the unbound stain. The plates were air dried and the bound stain was
dissolved in 150 !1 10 mM tris base (tris(hydroxymethyl)aminomethane). The absorbance was
read at 540 nm using an automated microplate reader (Labsystems Multiskan MS). Data were
used for construction of concentration-response curves and determination of the IDo (dose
where 50% of the cells are inhibited) value by use of Deltasoft 3 software. For further details
on the test methodology, see refs. [13-15].
In Table I, IDo values of some well known oncology drugs are presented. IDovalues may
show some variation due to the biological nature of the test. Slight changes in the system
during the years of testing may also cause changes in the IDo values. The actual reference
values can be found in the papers pertaining to the compounds.
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Table I: IDo values (ng/ml) of doxorubicin (DOX), cisplatin (CPT), 5-fluorouracil (5-FU),
methotrexate (MTX) and etoposide (ETO)
Drug
Cell line DOX CPT 5-FU MTX ETO
MCF7 10 699 750 18 2594
EVSA-T 8 422 475 5 317
WIDR 967 225 <3 150
IGROV 60 169 297 7 580
M19 MEL 16 558 442 23 505
A498 90 2253 143 37 1314
H226 199 3269 340 2287 3934
For the in vivo testing, the compounds were dissolved in ethanol or in DMSO, depending on
the solubility. Further dilution was either in 2% (w/v) carboxymethylcellulose in saline or in
arachidis oil to a concentration of 2 10 mg/ml.
The experiments were performed with 10 12 week old female Balb/c mice (Harlan/Cpb,
Zeist, NL). The animals were housed under standard conditions with water and food ad libitum.
MTD (median tolerated dose) studies were performed with groups of 2 mice, which were
treated weekly for two weeks by i.p. (intraperitoneal)injection (qdx2). Usually a steep dose
toxicity relation was found. For poorly soluble compounds the toxicity often was
unpredictable. This may cause delay in the initiation of anti-tumor experiments.
The murine colon tumor Co 26 (variant Co 26A) was maintained in Balb/c mice by s.c.
(subcutaneous) transplantation in both flanks in the thoracic region in small fragments of 1 5
mm. When tumors had reached a volume of 50 150 mm treatment was started. Tumor size
was determined by calliper measurement (length x width x height x 0.5) twice a week. The
volume of the tumours was expressed relative to that on the first day of treatment (day 0).
Before treatment mice were randomized in groups, one as a control group and the other
groups for treatment. Each group consisted of at least 6 mice. Mice were treated by a single
i.p. injection. Anti-tumor activity was evaluated by calculation of the TIC (relative tumor size
of the treated (T) mice divided by the relative tumor size of the control (C) mice) and the
increase of median life span (ILS). Median life span was calculated from the first day of
treatment. See ref. [16] for further experimental details. For the murine leukemia L1210, see
ref. [10].
In vitro tests were carried out in the Laboratory for Tumor Biology and Pharmacology of the
Academic Hospital Rotterdam, The Netherlands. In vivo tests were carried out by the
Department of Medical Oncology of the Free University of Amsterdam, The Netherlands under
the supervision of Dr G. J. Peters.
Results and Discussion
Many organotin compounds have been synthesized in the past years. From these
compounds, a selection will be presented. As a first example of structurally interesting
compounds, a series of organotin derivatives of 1,2- and 1,7-dicarba-closo-dodecaboranes will
be discussed. These novel compounds were prepared from dicarboranyltin dichloride [17,18].
They were tested in vitro in the human tumor panel. Their IDso values are summarized in Table
II. Compound 1 is o-CBoH, compound 2 (m-CBoH-9)SnCI and compound 6 2-phenyl-l,2-
carborane-l-carboxylic acid.
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Table I1: IDo values (ng/ml) of some dicarboranyltin compounds
Cell line









410 3 30 110
42426 58292 >60000 55032 11747
514 169 220 301 388
102 172 182 246 140
As can be seen from Table II the carboranyltin derivatives show considerable activity
compared with the carboranes 1 and 6 and the reference cisplatin. Because of its high
activity, compound 4 was tested also in vivo in the mouse intraperitoneal (ip) L1210 tumor.
Doses of 7, 10, and 14 mg/kg were administered ip. At 10 mg/kg the TIC value was 145 (TIC
activity criterium for the L1210 > 125). At the dose of 7 mg/kg there was 1/6 long term survivor.
Another type of active organotin compounds are the triphenyltin derivatives [19]. The in
vitro activity of two examples is summarized in Table II1.
X
Sn ’
9 X = SO3H
10 X = NH2
Table II1: IDo values (ng/ml) of two triphenyltin compounds
Cell line
Compound MCF7 EVSA-T WIDR IGROV M19 MEL A498
9 510 400 1100 290 105 510
10 200 180 590 490 1100 700
Before compounds 9 and 10 were tested in vivo in the murine Co 26, their in vitro activity in
this tumor was assessed: IDo of compound 9 was 290 and of 10 97 ng/ml. The IDo of cisplatin
was 276 ng/ml. The compounds 9 and 10 were as active in vitro as cisplatin or more active.
Toxicity testing in vivo gave for 9 and 10 MTD values of 5-6 and 8 mg/kg. Although this
difference may seem small, compound 9 was highly toxic: paralysis was observed. In the in
vivo Co 26 compound 9 showed a TIC of 80% and an ILS of 111%, compound 10 gave a TIC
of 71% and an ILS of 100%. In this test, the compounds were not active (activity limit for the
Co 26 T/C < 42%, ILS > 125%). The TIC of cisplatin, 5.5 mg/kg administered weekly for 4
weeks, was 73% and 39% at the dose of 9 mg/kg.
The test results obtained were encouraging, but there was a practical problem that should
be mentioned now already: the solubility. In order to be administered to cancer patients,
cytostatics should be soluble in water. Additives can be used to improve the solubility. Also for
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in vivo testing in animals, the compounds have to possess hydrophilic properties. Compounds
1-10 had to be dispersed in the solvent or dissolved by using an ultra-sonic bath.
Extensive research towards the effect of fluorine substitution in the aryl group of the
carboxylate bound to the tin atom has been carried out. A range of fluorine-substituted tin
benzoates has been synthesized [20-25] and their in vitro antitumor activity assessed. The data
of selected compounds have been summarized in Table IV.
Table IV: IDa0 values (ng/ml) of selected tin fluorine-substituted aromatic carboxylates
Ref. Cell line
Compound MCF7 WIDR
11 {[(2-FCeH4COO)(n-Bu)Sn]O} 20 91 330
1 2 {[(4-FCeH4COO)(n-Bu)Sn]O} 20 81 360
1:3 {[(3-FC6H4COO)(n-Bu)Sn]O} 20 496 3431
14 (3-FC6H4COO)Sn(n-Bu) 20 39 271
1 , (2,3-FCeHCOO)Sn(n-Bu) 22 23 283
1 6 {[(2,3-FC6HCOO)(n-Bu)Sn]O} 22 9 120
17 {[(2,5-FCeHCOO)(n-Bu)=Sn]=O}= 22 7 277
18 (3,5-FCeH3COO)=Sn(n-Bu)= 22 30 407
1 9 {[(2,6-F=CeHCOO)(n-Bu)Sn]=O}= 22 3 174
20 {[(3,5-FCeH3COO)(n-Bu)=Sn]O} 22 11 172
21 {[(2-FCeH4CH=CH-COO)(n-Bu)=Sn]O}= 21 28 368
22 4-FCeH4COOSnPh 19,23 15 14
:23 3-FCeH4COOSnPh 23,24 10 12
24 3,5-F=CeHCOOSnPh 23 18 17
25 2,3-F=CeH3COOSnPh 23,24 31 24
26 2,6-F2CeH3COOSnPh 19,25 8 <1
The compounds 22 and 26 were also tested in vivo in the Co 26 model [19]. Compound 22
gave at a dose of 6 mg/kg a T/C of 67% and an ILS of 111%, compound 26 yielded at a dose
of 5 mg/kg a T/C of 87% and an ILS of 111%. Both compounds were judged to be not active in
the Co 26 test.
in order to further explore new structural elements and to improve the solubility of the
compounds, novel derivatives containing the dihydroxybenzoate [26] and the
perfluorobenzoate [27] moieties were prepared. These compounds were tested in vitro and
found to display promising activity. Some selected results are summarized in Table V.
Table V: IDo values (ng/ml) of dihydroxy- and perfluorobenzoatotin compounds
Cell line
Compound MCF7 EVSA-T WIDR IGROV M19 MEL A498
27 [2,4-(OH)=C6HCOO]=Sn(n-Bu)= 16 54
28 [2,6-(OH)=C6HCOO]Sn(n-Bu) 15 58
29 [2,3-(OH)CeH3COO]Sn(n-Bu)= 7 43
30 [3,5-(OH)=CeHCOO]Sn(n-Bu)= 130 30
31 [2,5-(OH)CeHCOO]Sn(n-Bu) 4 48
32 {[(C6FCOO)(n-Bu)=Sn]O} 44 39
33 {[(C6FCHCOO)(n-Bu)Sn]O} 55 43
34 (C6FCHCOO)Sn(n-Bu) 10 19
3, {[(CeFCH=CHCOO)(n-Bu)Sn]O} 32 37
120 85 58 130
130 110 65 130
90 51 50 50
500 120 190 280
115 60 65 100
214 53 86 76
275 60 114 105
145 20 36 50
234 41 66 135
The introduction of a polar group leads to some improvement in the solubility and definitely
to considerable in vitro activity. Four of the compounds were tested in vivo in the murine Co 26
model [28]. A summary of the results is given in Table VI. Only compound 34 showed modest
activity. Toxicity was mainly gastrointestinal.
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Table VI: In vivo Co 26 test results of four orqanotin compounds
Compound Dose Schedule TIC ILS
mg/kg % %
27 6 qd7x2 87 100
31 5 single 63 111
5 qd7x2 60 97
33 10 qd7x2 120 97
34 16 qd7x2 63 126
Based on earlier work, selected organotin steroidcarboxylates have been synthesized [29].
The new compounds 36-42 have been tested in vitro and the results are summarized in
Table VII.










40 RI=R3=R2: =O; R’=C6H5
41 R1 = OH; R2 = R3 = H; R’= C6H5
42 R1 = OH; R2 = R3 = H; R’= n-C4H9
Table VII: IDo values of selected organotin steroidcarboxylates
Compound Cell line
MCF7 EVSA-T WIDR IGROV M19 MEL A498 H226
36 18 <3 36 18 51 42 61
37 160 60 390 160 120 220 420
38 409 171 629 150 481 972 1229
39 18 <3 15 17 32 53 53
40 11 <3 22 16 22 11 50
41 16 <3 19 18 51 65 61
42 16 <3 15 <3 51 138 76
The compounds 36-42 displayed appreciable in vitro anti-tumor activity. Compounds 36
and 37 were also studied in vivo in the murine Co 26 tumor model. The compounds appeared
to be so toxic in the tumor bearing mice that a second injection could not be given. The
toxicity was higly variable due to the poor solubility of the compounds, which were
administered as a dispersion in arachidis oil. The solubility of compound 36 in DMSO was
poor, that of compound 37 good. After administration qd7xl at a dose of 15 mg/kg compound
36 gave a T/C of 42% and an ILS of 8%, compound 37 gave a T/C of 77% and an ILS of 30%.
185Vol. 5, No. 4, 1998 Preface." The Development ofNovel Organotin Anti-Tumor Drugs."
Structure and Activity
Compound 36 thus showed activity in the Colon 26 in mice.
The tin steroidcarboxylates appeared to possess considerable in vitro anti-tumor activity, but
solubility still remained a drawback, which affected their in vivo properties. In order to make this
type of compounds more soluble, another structure, which contained again a five ring moiety,
but now also polar substituents, was designed. This led to the synthesis of organotin terebates




44 R n-C4H9 45 R C6H5
Table VIII’ IDo values of some orqanotin terebates
Compound MCF7 EVSA-T WIDR IGROV M19 MEL A498 H226
43 27 25 134 18 61 61 104
44 3 <3 11 4 11 15 8
4, 17 <3 17 19 42 42 39
Again the novel organotin compounds were found to have high in vitro anti-tumor activity.
Compounds 43-4, were tested also in vitro in the mouse Colon 26 [31]. The solubility of
compounds 43 and 44 in DMSO was good, that of 4, poor. The DMSO solution was further
diluted with arachidis oil, resulting in a colloidal suspension. The toxicity of the compounds
was unpredictable and variable, probably as a result of the limited solubility. There was again
considerable toxicity. Only one injection of compound 4, could be given. Two injections of
compound 44 resulted in 3/5 toxic deaths in one week. The results of the in vivo tests are
summarized in Table IX. Some in vivo activity was detected.
Table IX: In vivo activity of some organotin terebates in the murine Co 26 model
Compound Dose Schedule T/C
mg/kg %
43 5 qd7x2 91
44 10 qd7x2 121






Many organotin compounds have been synthesized during recent years. Test results made
clear that considerable in vitro activity has been detected in several types of organotin
compounds, as has been demonstrated in the selection presented in this paper. Often in vitro
activity was higher than that of cisplatin and sometimes organotin compounds possessed
activity comparable with that of doxorubicin.
The development process led to compounds with definite pharmacological activity: anti-
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tumor activity in vivo, but also toxicity. Incidentally neurotoxicity, known from cisplatin and
oxaliplatin, was detected. The in vivo testing was affected by the limited water solubility of the
compounds. This is one of the most important factors emerging from the evaluation of the
results. The lack of water solubility prevented the use of aqueous solutions in the in vivo tests
and necessitated the use of arachidis oil for the preparation of a suspension.
The organotin compounds require, as do cisplatin derivatives, a structural moiety
containing two substitutable leaving groups forming an angle with the metal, which should lie
typically between 90
o (cis configuration in cisplatin) and no more than 120, including the
typical tetrahedral geometry (109.5). The presence of substituents containing a steroid moiety
or a carboranyl group enhances the in vitro activity. It is not yet clear whether this is the effect
of the substituent such as the steroid group or the size of the group. Also the presence of
structural units containing a polar substituent contributes to higher activity. A polar substituent
may also increase the water solubility of the compounds.
Some compounds such as the organotin terebates merit more detailed investigation.
Further chemical and pharmacological studies are necessary to unravel a structure-activity
relationship from which novel organotin anti-tumor drugs for use in patients can be developed.
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